v3.25.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies [Abstract]  
Schedule of Milestone Payments that the Group is Required to Pay up to Different Achievements The aggregate amounts of the contingent milestone payments that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as of December 31, 2024 are below:
   Amount 
Drug molecules: up to the conditions and milestones of    
Preclinical to IND filing  $30,000 
From entering phase 1 to before first commercial sale   2,120,000 
First commercial sale   1,600,000 
Net sales amount more than certain threshold in a year   14,000,000 
Subtotal  $17,750,000 
      
Diagnostics technology: up to the conditions and milestones of     
Before FDA approval  $146,417 
   $17,896,417